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Objectives: To assess factors affecting physicians’ decision on why they did not 
initiate dual therapy to untreated Type 2 Diabetes Mellitus (T2DM) patients with 
A1C 7.6–9% per AACE/ACE recommendation. MethOds: Primary care physicians 
(PCPs) and specialists in the US were asked to provide medical chart reviews for 4 
patients who were diagnosed with A1C 7.6-9% and initiated with metformin mono-
therapy. Physicians rated 22 reasons on a 5-point Likert scale (1-most irrelevant; 
5-most relevant) on how relevant each reason was for them in treating a specific 
patient. Top 5 reasons ( ≥ 50% of physicians rating the reason as 4 or 5) were identi-
fied. Association of each reason on physician specialty or age was conducted using 
mixed-effect model controlling for physician and patient characteristics. Results: 
1,235 PCPs and 290 specialists participated the study and provided reviews for 5,995 
patients (3,009 young and 2,986 elderly). Four relevant reasons were related to phy-
sicians attitudes and beliefs toward metformin monotherapy and dual therapy: 
R1-“Metformin monotherapy is sufficient to improve glycemic control” (mean[sd]: 
3.66[1.1]); R2 - “Monotherapy is easier to handle than dual therapy” (3.53[1.2]); R3- “I 
believe that monotherapy and changes in lifestyle (e.g. physical activity and dietary 
change) are enough for hyperglycemia control” (3.47[1.1]); and R4- “I recommend 
monotherapy before considering dual therapy” (3.75[1.1]). One relevant reason was 
related to physicians’ perception of patients’ glycemic level: R5 -“Patient has mild 
hyperglycemia” ” (3.27[1.1]). PCPs rated the four reasons more relevant than special-
ists (estimate,[95% CI]) (R1: 0.18,[0.05,0.30]; R2: 0.37,[0.24,0.50]; R3: 0.33,[0.20,0.46]; 
R4: 0.36,[0.23,0.49]. All p< 0.01). Lowering age was also more relevant in the four 
reasons (R1: -0.04,[-0.06,-0.02]; R2: -0.03,[-0.05,-0.02]; R3: -0.02,[-0.03,0.00], R4: -0.06,[-
0.07,-0.04]. All p< 0.02). cOnclusiOns: Guideline non-concordance is related to 
physicians’ attitudes and beliefs toward the therapies and perception of A1C above 
8% as “mild”. The findings have implications for improving T2DM treatment quality.
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aMong PrivatEly insurED MEDicarE PatiEnts
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Objectives: To describe changing diabetes treatment pattern among the elderly 
type 2 diabetes (T2DM) patients during the past 7 years. MethOds: A large retro-
spective Medicare patient claims data (MarketScan® Medicare) was longitudinally 
analyzed from 2005 to 2011 to understand T2DM medication use trend. The study 
included 4 major oral antidiabetic medications (i.e., metformin (MET), sulphony-
lurea (SU), thiazolidinediones (TZD), and dipeptidyl peptidase 4 inhibitor (DPP-4)) 
plus injectables (insulin and glucagon-like peptide 1 (GLP-1)) and reported patterns 
of therapy regimens and trends over time. Results: The study identified 453,045 
patients with 1 year enrollment and with T2DM taking one or more antidiabetic 
medications in 2011, compared to 283,484 patients in 2005. The frequently used 
mono therapies in 2011 are MET (22.1%), insulin (12.0%) and SU (10.8%), followed 
by TZD (2.6%), DPP-4 (2.0%), GLP-1 (0.28%). The percentage of patients using MET 
monotherapy increased from 15.0% in 2005 to 22.1% in 2011, while the percentage 
of patients using SU alone decreased from 16.6% in 2005 to 10.8% in 2011. Patients 
taking DPP-4 only increased from 0.03% in 2006 to 2.0% in 2011. Among the combi-
nation therapies in 2011, the most popular one was MET+SU (12.2%), followed by 
MET+DPP-4 (2.9%), MET+SU+DPP-4 (2.8%), MET+TZD (2.8%) and MET+SU+insulin 
(2.3%). The percentage of patients taking any type of insulin rose by 3.4 on from 
24.7% in 2005 to 28.1% in 2011. cOnclusiOns: This study shows changing trends 
in different classes of diabetes medication in this large sample Medicare patients 
over time. Continuing research is needed to monitor anitdiabetic treatment pattern 
change in the future and to understand how these changes are helping to improve 
diabetes care and outcomes.
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MEDication aDhErEncE anD sWitching ratEs of PatiEnts With 
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Objectives: To assess medication adherence and switching rates of testosterone 
replacement therapy (TRT) in the US. MethOds: We conducted a retrospective 
claims database study using the MarketScan® Commercial database from January 
2005 through December 2011. The study included men 18-65 years of age who 
had initiated TRT and were diagnosed with hypogonadism or hypogonadotropic 
hypogonadism (ICD-9-CM: 257.3 and 257.4). A minimum of 6 months continuous 
enrollment before and 12 months after the TRT index date was required. Adherence 
was measured by the Mediation Possession Ratio (MPR) and the Proportion of Days 
Covered (PDC), with the adherence rate defined as MPR≥ 0.8. The rate of the first 
switching was summarized by TRT formulation. Results: Of 106,039 patients with 
hypogonadism, the mean MPR and the mean PDC of any TRT during the 360 days 
study period was 0.47 and 0.44, respectively. The overall adherence rate over 12 
months was 21.4% ranging from 28% (pellets), 19.9% (SAIs), 17.7% (gels), 7.8% (buc-
cal), and 6.6% (patch), respectively. Similarly, the average PDCs were significantly 
higher for pellets (0.59) compared to gels (0.43), SAIs (0.39), buccal (0.28), and patch 
(0.27) (P< 0.001). About 13% (n = 13,577) of patients switched from their initial therapy 
to a different TRT formulation. Patients starting with patch were most likely to 
switch to a different formulation (39.3%), followed by patients with SAIs (12.1%), pel-
lets/buccal (12.0%), and gels (10.3%). cOnclusiOns: Our study showed low adher-
ence rates of testosterone replacement therapy among hypogonadism patients. The 
adherence for patients starting on the long-acting testosterone formulation such 
Simulations estimated 1- and 3-year HbA1c progression for 1000 hypothetical 
T2DM patients (average 7 (SE 5.1) years post-diagnosis) to obtain the propor-
tion meeting criteria for < 7%, < 8% and > 9% thresholds by bootstrapping the UK 
Prospective Diabetes Study (UKPDS) 68 equation. UKPDS68 accounts for time, 
HbA1c in the prior year, drug treatment effect, and baseline A1c. Parameter values 
for duration of diabetes, baseline HbA1c, and treatment effect were selected from 
distributions around the mean, and mean values of the latter two were system-
atically varied to approximate different populations and effects. Results: By 1 
year, all NCQA requirements are met when treating patients with alo-pio if aver-
age baseline HbA1c is ≤ 8%. At 3 years, all requirements are met in patients with 
baseline HbA1c ≤ 7.2%, though 8% and 9% threshold requirements are feasible with 
higher baseline HbA1c. Using a more realistic thiazolidinedione durability assump-
tion (annual rosiglitazone HbA1c increase) instead of UKPDS68, all thresholds are 
met at 1 year ≤ 8% baseline HbA1c, and at 3 years with ≤ 7.4% baseline HbA1c. The 
7% and 8% requirements are met with ≤ 8.2% baseline HbA1c at 1 year; at 3 years, 
8% and 9% thresholds can be met with baseline HbA1c ≤ 8-8.2%. cOnclusiOns: 
The simulations show that clinical thresholds can be met at 1 and 3 years, indi-
cating that alo-pio can be considered for treating an appropriate population from 
an ACO perspective.
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Objectives: Health technology assessment (HTA) agencies and reimbursement 
authorities typically require evidence from randomised controlled trials (RCTs) to 
assess the comparative effectiveness of drugs. For example, for an assessment of 
the GLP-1 receptor agonist exenatide for management of Type 2 diabetes mellitus 
(T2DM), the German Federal Joint Committee (G-BA) pre-specified comparators of 
interest for short- (Byetta®) and long-acting exenatide formulations (Bydureon®) 
in seven indications. The aim of this research was to assess the availability of 
direct or indirect evidence for the benefit of exenatide to support an HTA sub-
mission to the G-BA. MethOds: A systematic literature review was conducted 
to identify RCTs comparing exenatide with pharmacological interventions in 
patients with T2DM. Electronic databases (Medline, Embase, Cochrane library: 
accessed October 2013) and clinical trial registries were interrogated. Results: Of 
twenty-nine Byetta® RCTs identified, twenty-seven were inappropriate to provide 
evidence to the G-BA for the following reasons: use of a non-pre-defined compara-
tor (n= 13), background treatment not requested by G-BA (n= 12), or administration 
of a non-licenced Byetta® dose (n= 2). The remaining two studies provided direct 
evidence for two indications. None of the eight Bydureon® RCTs identified were 
appropriate for direct analysis: use of a non-G-BA-required background treat-
ment (n= 7) or comparator (n= 1). For the five indications where no direct evidence 
was available, a single RCT investigating Bydureon® was identified which could 
potentially be used in an indirect comparison against a G-BA required compara-
tor. cOnclusiOns: Despite identification of over thirty RCTs investigating exena-
tide, most of the available evidence would not be considered appropriate by the 
G-BA to assess the benefit of exenatide despite having formed the basis for regula-
tory approval. Regulatory and HTA agencies, reimbursement authorities, and the 
pharmaceutical industry should be aligned on appropriate RCT design to ensure 
the generation of relevant evidence, although this may be challenging given the 
dynamic diabetes treatment environment.
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Objectives: Maintaining glycemic control for patients with type 2 diabetes (T2D) 
is associated with a reduced risk of future complications. Proper patient aware-
ness of HbA1c is important to facilitate adherence and improve outcomes. This 
study profiles how HbA1c awareness has changed over time and the consequences 
of poor awareness. MethOds: Data from the 2006-2013 US National Health and 
Wellness Survey (NHWS) were used in the analysis (Ns = 62,834 to 75,000 in each 
year). The NHWS is an annual, patient-reported, cross-sectional survey fielded to 
match the demographic characteristics of the US adult population. Patient aware-
ness of their HbA1c levels (i.e., a reported value vs. a “don’t know” response) was 
examined each year. Differences between those who were aware versus unaware 
were made with respect to health status (using the SF-36v2), work productivity 
loss (using the WPAI-GH), and health care resource in a series of regression models 
controlling for demographics and health characteristics. Results: Awareness of 
HbA1c levels improved from 26.6% (in 2006) to 56.4% (in 2013). In 2013, patients who 
are aware (n= 4658) were more likely to be older (60.5 vs. 57.2 years), non-Hispanic 
white (71.4% vs. 61.1%), treating with oral/insulin/non-insulin injectable (87.8% vs. 
76.1%), and more likely to have had diabetic complications compared with those 
who were unaware (n= 3040; all p< .05). Holding demographics and health history 
constant, lack of awareness was associated with poorer health utilities (0.70 vs. 0.68), 
more overall work impairment (17.9% vs. 20.8%), and more hospitalizations in the 
past six months (0.26 vs. 0.22), among other outcomes (all p< .05). cOnclusiOns: 
Awareness of HbA1c has increased over time, though appears disproportionately 
higher among patients of high socioeconomic status and higher risk (i.e., those with 
complications and using insulin). Awareness was also independently associated 
with poorer health outcomes suggesting improved patient education may have 
significant societal benefits.
